Geopharma is a company engaged in the Research, Development, Manufacturing, and Marketing of branded generic pharmaceuticals, veterinary products, health products, and functional foods. Our Company has two primary goals: to provide high-quality pharmaceuticals and health related products that improve the health of our customers, and to operate as an ethical and honorable corporate citizen. We work to fulfill these goals by enhancing our existing products as well as by developing important new products to treat a wide variety of illnesses.

GeoPharma has more than 200,000 square feet of facilities located outside Tampa, Florida. The facilities accomodate the business operations including product manufacturing, packaging/labeling, and a quality control laboratory. Manufacturing operators, Facilities and documentation comply with current good manufacturing practices (cGMP). GeoPharma is registered with both the Food and Drug administration and the Drug Enforcement administration.

GeoPharma, through American Antibiotics, has approximately 100,000 square feet of manufacturing dedicated to Beta-Lactam antibiotics in Baltimore, Maryland. This facility currently possesses several ANDA's. GeoPharma, through one of its Belcher Pharmaceuticals facilities has approximately 10,000 square feet (soon to be 20,000) dedicated to the Cephalosporin antibiotics. Currently Belcher Pharmaceuticals owns an ANDA for Cephalexin.

The business environment in which GeoPharma participates is dynamic. External factors such as population demographics and healthcare funding/expenditures continue to present new challenges. The organization is dedicated to meeting the presenty and future needs of the healthcare marketplace and correspondingly, has allocated substantial resources to aggressively pursue the development of off-patent pharmaceutical products. The company's employees are devoted to the application of sound scientific fundamentals and the process of continuous improvement to make a worthwhile contribution to the well-being of its customers.

To keep pace with this demand and leverage the market's potential, GeoPharma has invested significant resources into building an infrastructure and capacity for unique and niche related generic pharmaceuticals. With the addition of dedicated Cephhalosporin, as well as Beta-Lactam facilities, GeoPharma expects to be a dominant player in the Antibiotic segment.